News and media

| 27/12/2017

Here's holiday reading that provides hope for a world without MND. Settle back and take a look at the December issue of the MND Australia International Research Update to find out the latest advances in MND research worldwide.

| 21/12/2017

A Phase 2 clinical trial to investigate the safety, tolerability and effectiveness of a drug called Tecfidera in people with MND will begin in Australia in February 2018.

| 20/12/2017

In 2016 – 17 MND Australia delivered on the milestones and targets in our Strategic Plan 2015 – 2018. The MND Australia Annual Review outlines major accomplishments in advocacy, raising awareness, information provision and supporting research.

| 19/12/2017

The latest issue of Advance is online featuring highlights from recent MND research events, an overview of The Lighthouse Project clinical trial and an interview with Drs Shyuan Ngo and Frederik Steyn. 

| 20/11/2017

An international research team has advanced our understanding of the genetic factors contributing to the risk of developing motor neurone disease (MND).

The research, partly supported by the MND Research Institute of Australia (MNDRIA), investigated the NEK1 gene in 610 Chinese people with MND compared to people without MND.
 
 

| 16/11/2017

The MND Research Institute of Australia is proud to share its report, $25 Million, 25 Milestones: Changing the future of motor neurone disease. Launched at the 13^th MND Australia Research Conference by the Assistant Minister for Health, the Honourable Dr David Gillespie MP, the report details 25 high-impact MNDRIA-funded advancements, which are helping to change the future of MND and bringing hope to people living with MND.

| 14/11/2017

The MND Research Institute of Australia has awarded more than $3.31 million for research to start in 2018. Following review of grant applications by the MNDRIA Research Committee, 28 new research projects will be supported next year.

| 19/10/2017

The Productivity Commission has released its report on National Disability Insurance Scheme (NDIS) costs. MND Australia welcomes the report, which has reflected concerns from organisations across the disability sector. MND Australia made a submission to the Productivity Commission, outlining our concerns about the current NDIS process, and suggestions for improvement, many of which have been noted in the report.

| 16/10/2017

Through her role as Chairwoman of the International Alliance for ALS/MND, our CEO, Carol Birks, was privileged to experience different cultures’ approaches to MND care and support. With visits to Myanmar and Israel, the trips were a great opportunity to see the exciting progress in MND research and care internationally. Differences were underpinned by a common passion and commitment to improve the lives of people living with this devastating disease and their families.

| 13/10/2017

National Carers Week 2017 will run from 15 – 21 October and is an opportunity to appreciate and celebrate the invaluable contribution that Australia’s 2.7 million unpaid carers make every day. In Australia, the economic impact of informal care costs of people living MND totals $68.5 million - or $32,728 per person with MND. This financial strain highlights the serious reliance the system currently places on family carers to support people living with motor neurone disease. Carers make an enormous contribution to our communities and our nation and it is important that they are recognised.